Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Autoimmunity Reviews|September 19, 2016
Cognitive disorders and antiphospholipid antibodiesCécile M Yelnik, Elizabeth Kozora, Simone AppenzellerCurrent Rheumatology Reports|March 1, 2016
Non-stroke Central Neurologic Manifestations in Antiphospholipid SyndromeCécile M Yelnik, Elizabeth Kozora, Simone AppenzellerArthritis Care & Research|October 18, 2016
Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus PatientsCécile M Yelnik, Monica Richey, Virginia Haiduc, et al.Lupus|July 13, 2022
Dyslipidemia is insufficiently treated in antiphospholipid syndrome patientsCécile M Yelnik, Claire Martin, Emmanuel Ledoult, et al.International Journal of Clinical Practice|March 2, 2021
National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohortMohammad Ryadh Pokeerbux, Cécile M Yelnik, Emmanuel Faure, et al.Retina (Philadelphia, Pa.)|April 12, 2021
CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND POSTERIOR OCULAR INVOLVEMENT: Case Series of 11 Patients and Literature ReviewNathalie Morel, Clémence Bonnet, Hanane Mehawej, et al.Medicine|September 30, 2016
Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literatureSébastien Sanges, Cécile M Yelnik, Olivier Sitbon, et al.Rheumatology (Oxford, England)|October 3, 2022
Determination of four homogeneous subgroups of patients with antiphospholipid syndrome: a cluster analysis based on 509 casesYann Nguyen, Cécile M Yelnik, Nathalie Morel, et al.Eclinicalmedicine|June 23, 2023
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trialStéphane Zuily, Benjamin Lefèvre, Olivier Sanchez, et al.Pageof 1